AMDR’s Action Alerts and Technical Tips provide awareness and guidance on important industry developments that could impact your facility’s ability to deliver affordable, sustainable healthcare. Some of our Alerts are directly inspired by what was exposed in the case:

August 28, 2025: Court Prohibits Certain Anti-Reprocessing Tactics Following Innovative Health v. Biosense Webster Verdict

A federal court has issued a permanent injunction barring Johnson & Johnson’s Biosense Webster unit from interfering with reprocessing, following a trial in which the jury found the company liable for unlawful tying and monopolization. The court has barred Biosense from tying case support to device purchases, disabling reprocessed devices with chips, and hoarding used devices to cut off reprocessors’ supply.

This Action Alert explains the ruling, what hospitals should watch for, and how to report violations.

June 30, 2025: Reporting OEM Anti-Reprocessing Interference Following Innovative Health v. Biosense Webster Verdict

A federal jury has found a major OEM liable for unlawful tying and monopolization. AMDR has created a short form so hospital staff, supply chains, and reprocessors can report anti-reprocessing interference and route evidence to the right authorities. Reports may be submitted anonymously.

Read the Action Alert for the checklist of what to document, who to notify internally, and the downloadable reporting form.

June 12, 2025: Misleading Promotional Tactics by Medtronic Regarding Pulse Oximeter Sensors

Medtronic is marketing reprocessed Nellcor™ sensors as “remanufactured”—a label their FDA clearance doesn’t support—while pushing misleading superiority claims. They also limit sensors to one reprocessing cycle, inflating waste and emissions, while FDA data show multiple safe cycles are possible. Hospitals should verify claims against FDA filings, demand independent validation, and report misleading marketing.

Read the Action Alert for what to watch for, the questions to ask vendor reps, and next steps.